Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
IPO Year:
Exchange: NASDAQ
Website: aptevotherapeutics.com
Roth Capital reiterated coverage of Aptevo Therapeutics with a rating of Buy and set a new price target of $50.00 from $64.00 previously
NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ
4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)
SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)
SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)
SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)
SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)
SC 13D/A - Aptevo Therapeutics Inc. (0001671584) (Subject)
SC 13D/A - Aptevo Therapeutics Inc. (0001671584) (Subject)
SC 13D/A - Aptevo Therapeutics Inc. (0001671584) (Subject)
SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)
SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)
Potential to redefine frontline AML treatment being evaluated in clinic: Mipletamig, CD3 x CD123 bispecific, in combination with standard of care, offers a multi-mechanism strategy for potential improved patient outcomesFavorable early safety, efficacy, tolerability and durability of remission data informed Aptevo's ongoing RAINIER Phase 1b/2 trialSEATTLE, WA / ACCESSWIRE / November 20, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today expanded on the potential of mipletamig, currently being evaluated as frontline
Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable diseaseColon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 monthsBiomarker analysis confirms immune activation in the tumor microenvironmentData Presented at Society for Immunotherapy of Cancer on November 8, 2024 SEATTLE, WA and LUND, SWEDEN / ACCESSWIRE / November 11, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB ("Alligator") (ATORX) today announced preliminary data from the
Company Achieves Milestones in Both Clinical ProgramsInitiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by Positive Dose Escalation Trial ResultsPresented Interim Data from ALG.APV-527 Phase 1 Trial in Multiple Solid Tumors at the European Society for Medical Oncology CongressAdditional Favorable Data to be Presented at the Society for Immunotherapy of Cancer Conference on November 9thRaises $5.75 Million in the QuarterSEATTLE, WA / ACCESSWIRE / November 7, 2024/ Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAP
SEATTLE WA AND LUND, SWEDEN / ACCESSWIRE / October 29, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB ("Alligator") (ATORX) today announced that new, positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 will be presented in a poster session on Friday, November 8, 2024, at the Society for Immunotherapy of Cancer 2024 (SITC), taking place November 6th - 10th, 2024 in Houston, Texas.Presentation DetailsPoster number: #673Title: Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4 × 4-1BB bispecific antibody, in patients with advanced solid tumors demonstrate favorable safety and biological a
SEATTLE, WA / ACCESSWIRE / September 18, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 9,090,910 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 18,181,820 shares of its common stock (the "Common Warrants") at a purchase price of $0.33 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being o
SEATTLE, WA / ACCESSWIRE / September 16, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it has entered into securities purchase agreements with certain healthcare-focused and institutional investors to purchase (i) 9,090,910 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 18,181,820 shares of its common stock (the "Common Warrants") at a purchase price of $0.33 per share and associated Common Warrant in a registered direct offering pr
Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor TypesProlonged stable disease lasting >11 months demonstrated in Breast Cancer PatientFavorable Pharmacokinetics, Safety and Tolerability ObservedData Presented at the European Society of Medical Oncology on September 14, 2024 SEATTLE WA and LUND, SWEDEN / ACCESSWIRE / September 16, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB ("Alligator") (ATORX) today announced positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors likely to express the tumor antigen 5T4. The results, which include clinical activity, sa
SEATTLE WA and LUND, SWEDEN / ACCESSWIRE / September 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB ("Alligator") (ATORX) today announced that positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 will be presented in a poster session on Saturday, September 14, 2024, at the European Society for Medical Oncology (ESMO) Annual Congress 2024, taking place September 13 th - 17 th , 2024 in Barcelona, Spain.Presentation DetailsPoster number: #668PTitle: First-in-Human Phase I Dose Escalation Study of ALG.APV-527, a 5T4 Tumor Antigen-Conditional 4-1BB Bispecific Antibody, in Patients with Advanced Solid Tumors, Demon
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidineCompany anticipates new data set to bolster existing compelling data reported to date, including efficacy outcomes more than double the benchmarks*Outcomes also expected to identify recommended Phase 2 doseAPVO436 renamed as mipletamig: Aptevo adopts new generic name for future useSEATTLE, WA / ACCESSWIRE / August 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today, announced initiation of t
SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update."After the successful completion of our APVO436 dose expansion trial, where we saw a 91% clinical benefit rate and an excellent safety, tolerability and duration of remission profile, we worked in the second quarter to finalize plans for the launch of the first part of our Phase 1b/2 trial, a dose optimization study, continuing evaluation of
8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)
10-Q - Aptevo Therapeutics Inc. (0001671584) (Filer)
8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)
8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)
8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)
DEF 14A - Aptevo Therapeutics Inc. (0001671584) (Filer)
PRE 14A - Aptevo Therapeutics Inc. (0001671584) (Filer)
8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)
424B4 - Aptevo Therapeutics Inc. (0001671584) (Filer)
EFFECT - Aptevo Therapeutics Inc. (0001671584) (Filer)
Shares of Domino’s Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results. The company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion. The company is temporarily suspending its guidance metric of 1,100+ global net stores growth until the full effect of DPE's store opens and closures on international net store growth are known. Domino’s Pizza shares dipped 11.2% to $420.36 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Onconetix, Inc. (NASDAQ:ONCO) climbed 97.6% to $0.2944. On July 15, Oncon
Shares of Chuy’s Holdings, Inc. (NASDAQ:CHUY) rose sharply in today's pre-market trading after the company and Darden Restaurants, Inc. (NYSE:DRI) jointly announced that Darden will acquire Chuy's Holdings. Chuy's Holdings and Darden entered into a definitive agreement in which Darden will acquire all of Chuy's outstanding stock for $37.50 per share in cash. The all-cash transaction has an enterprise value of approximately $605 million. Chuy’s Holdings shares jumped 47.4% to $37.27 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Onconetix, Inc. (NASDAQ:ONCO) gained 65% to $0.2458 in pre-market trading. On July 15, Onconetix announced cl
Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation. ASLAN Pharmaceuticals shares dipped 38.7% to $0.68 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Aptevo Therapeutics Inc. (NASDAQ:APVO) shares climbed 84% to $0.6073 after surging around 10% on Tuesday. Aptevo Therapeutics recently announced closing of $2.75 million offering. Shimmick Corporation (NASDAQ:SHIM) shares climbed 49% to $3.0173 after the company received a $27.6 million subcontract for the Sunol Valley Water Trea
Shares of Bloom Energy Corporation (NYSE:BE) rose sharply in today's pre-market trading after the company announced a strategic partnership with CoreWeave. Bloom Energy said it entered into a partnership to deploy its proprietary fuel cells to generate on-site power for CoreWeave at a high-performance data center in Illinois. Bloom Energy shares jumped 12.1% to $16.90 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Shimmick Corporation (NASDAQ:SHIM) gained 53% to $3.09 in pre-market trading after the company received a $27.6 million subcontract for the Sunol Valley Water Treatment Plant Ozonation Project. Aptevo Therapeutics Inc. (NA
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it has entered into securities purchase agreements with certain healthcare-focused and institutional investors to purchase (i) 5,339,806 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 10,679,612 shares of its common stock (the "Common Warrants") at a purchase price of $0.515 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each sha
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 77.4% to $6.19 during Monday's pre-market session. The company's market cap stands at $3.5 million. ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 35.9% to $0.14. The company's market cap stands at $2.4 million. Venus Concept (NASDAQ:VERO) stock increased by 22.86% to $1.15. The company's market cap stands at $7.3 million. Tharimmune (NASDAQ:THAR) shares moved upwards by 19.4% to $4.0. The company's market cap stands at $3.1 million. TRACON Pharma (NASDAQ:TCON) stock moved upwards by 19.04% to $1.5. The market value of their outstanding shares is at $4.0 million. Kineta (NASDAQ:KA) shares moved upwards by
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2999138/summary.html
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(9.95) per share which beat the analyst consensus estimate of $(12.84) by 22.51 percent. This is a 76.92 percent increase over losses of $(43.12) per share from the same period last year.
Gainers NeuBase Therapeutics (NASDAQ:NBSE) stock increased by 11.1% to $0.45 during Friday's after-market session. The market value of their outstanding shares is at $1.6 million. Aptevo Therapeutics (NASDAQ:APVO) shares moved upwards by 7.17% to $1.06. The company's market cap stands at $3.8 million. Galera Therapeutics (NASDAQ:GRTX) shares moved upwards by 6.72% to $0.2. The market value of their outstanding shares is at $10.7 million. Alzamend Neuro (NASDAQ:ALZN) shares rose 5.85% to $0.77. The company's market cap stands at $5.2 million. Asensus Surgical (AMEX:ASXC) shares increased by 5.43% to $0.25. The company's market cap stands at $69.1 million. cbdMD (AMEX:YCBD) stock rose 5.